Early paracentesis is associated with better prognosis compared with late or no-paracentesis in hospitalized veterans with cirrhosis and ascites
- PMID: 36971257
- PMCID: PMC10523869
- DOI: 10.1097/LVT.0000000000000137
Early paracentesis is associated with better prognosis compared with late or no-paracentesis in hospitalized veterans with cirrhosis and ascites
Abstract
Guidelines recommend that all hospitalized patients with cirrhosis and ascites receive an early (<24 h from admission) paracentesis. However, national data are not available regarding compliance with and the consequences of this quality metric. We used the national Veterans Administration Corporate Data Warehouse and validated International Classification of Disease codes to evaluate the rate and subsequent outcomes of early, late, and no paracentesis for patients with cirrhosis and ascites during their first inpatient admission between 2016 and 2019. Of 10,237 patients admitted with a diagnosis of cirrhosis with ascites, 14.3% received an early paracentesis, 7.3% received a late paracentesis, and 78.4% never received a paracentesis. In multivariable modeling, compared with an early paracentesis: both late paracentesis and no-paracentesis were significantly associated with increased odds of acute kidney injury (AKI) development [OR: 2.16 (95% CI, 1.59-2.94) and 1.34 (1.09-1.66), respectively]; intensive care unit (ICU) transfer [OR: 2.43 (1.71-3.47) and 2.01 (1.53-2.69), respectively] and inpatient death [OR: 1.54 (1.03-2.29) and 1.42 (1.05-1.93), respectively]. Nationally, only 14.3% of admitted veterans with cirrhosis and ascites received the American Association for the Study of Liver Diseases (AASLD) guideline-recommended diagnostic paracentesis within 24 hours of admission. Failure to complete early paracentesis was associated with higher odds of AKI, ICU transfer, and inpatient mortality. Universal and site-specific barriers to this quality metric should be evaluated and addressed to improve patient outcomes.
Copyright © 2023 American Association for the Study of Liver Diseases.
Conflict of interest statement
Conflicts of interest:
Nilang Patel advises for Mallinckrodt Pharmaceuticals.
Jacqueline G. O’Leary advises for Grifols and Genfit. She consults for Abbvie. Timothy Morgan received grants from Genfit.
The remaining authors have no conflicts to report.
Comment in
-
Don't delay: Early paracentesis can save lives in hospitalized patients with cirrhosis and ascites.Liver Transpl. 2023 Sep 1;29(9):911-912. doi: 10.1097/LVT.0000000000000174. Epub 2023 May 11. Liver Transpl. 2023. PMID: 37162148 No abstract available.
-
Letter to the Editor: The impact of a paracentesis education program among junior doctors.Liver Transpl. 2024 Jan 1;30(1):E11. doi: 10.1097/LVT.0000000000000258. Epub 2023 Sep 19. Liver Transpl. 2024. PMID: 37729525 No abstract available.
References
-
- Bajaj JS, Kamath PS, Reddy KR. The Evolving Challenge of Infections in Cirrhosis. N Engl J Med 2021;384(24):2317–30. - PubMed
-
- Bajaj JS, Wong F, Kamath PS, Lai JC, O’Leary JG. Acute-on-Chronic Liver Failure. Am J Gastroenterol 2022;117(6):831–4. - PubMed
-
- Biggins SW, Angeli P, Garcia-Tsao G, Gines P, Ling SC, Nadim MK, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74(2):1014–48. - PubMed
-
- Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J, et al. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology 2019;156(5):1368–80 e10. - PubMed